Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia

Clinical Lipidology

Volumn 10, Issue 2, 2015, Pages 191-203

  Bell, Thomas A ^a   Graham, Mark J ^a   Baker, Brenda F ^a   Crooke, Rosanne M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense oligonucleotide; apoC III; cardiovascular disease; familial chylomicronemia syndrome; HDL; hypertriglyceridemia

Indexed keywords

ALIPOGENE TIPARVOVEC; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; ATORVASTATIN; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTISENSE THERAPY; APOC3 GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG EFFICACY; DRUG SAFETY; FAMILIAL CHYLOMICRONEMIA SYNDROME; GENE CONTROL; GENE MUTATION; HUMAN; HYPERTRIGLYCERIDEMIA; INJECTION SITE ERYTHEMA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84928548101     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.15.7     Document Type: Review

References (59)

1. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ. Res. 112(11), 1405-1408 (2013).
2. Batal R, Tremblay M, Barrett PH et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41(5), 706-718 (2000).
3. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19(3), 472-484 (1999).
4. Jong MC, Rensen PC, Dahlmans VE, Van Der Boom H, Van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wildtype and apoE knockout mice. J. Lipid Res. 42(10), 1578-1585 (2001).
5. Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr. Opin. Lipidol. 25(1), 35-39 (2014).
6. Yao Z, Wang Y. Apolipoprotein C-III and hepatic triglyceriderich lipoprotein production. Curr. Opin. Lipidol. 23(3), 206-212 (2012).
7. Sundaram M, Zhong S, Bou Khalil M et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J. Lipid Res. 51(1), 150-161 (2010).
8. Lee HY, Birkenfeld AL, Jornayvaz FR et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54(5), 1650-1660 (2011).
9. Altomonte J, Cong L, Harbaran S et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 114(10), 1493-1503 (2004).
10. Caron S, Verrijken A, Mertens I et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 31(3), 513-519 (2011).
11. Peters JM, Hennuyer N, Staels B et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor-deficient mice. J. Biol. Chem. 272(43), 27307-27312 (1997).
12. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19), 2088-2093 (1998).
13. Hernandez C, Molusky M, Li Y, Li S, Lin JD. Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid. Cell. Metab. 12(4), 411-419 (2010).
14. Kathiresan S, Melander O, Guiducci C et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nature Genet. 40(2), 189-197 (2008).
15. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466(7307), 707-713 (2010).
16. Holleboom AG, Karlsson H, Lin RS et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell. Metab. 14(6), 811-818 (2011).
17. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J. Clin. Endocrinol. Metab. 89(8), 3949-3955 (2004).
18. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 115(4), 450-458 (2007).
19. Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J. Am. Heart Assoc. 2(3), e000130 (2013).
20. Bobik A. Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. Circulation 118(7), 702-704 (2008).
21. Pollin TI, Damcott CM, Shen H et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322(5908), 1702-1705 (2008).
22. TG & HDL Working Group of the Exome Sequencing Project National Heart, Lung, and Blood Institute Loss-offunction mutations in APOC3, triglycerides, and coronary disease. N. England J. Med. 371(1), 22-31 (2014).
23. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. England J. Med. 371(1), 32-41 (2014).
24. Goldberg IJ, Eckel RH, Mcpherson R. Triglycerides and heart disease: still a hypothesis Arterioscler. Thromb. Vasc. Biol. 31(8), 1716-1725 (2011).
25. De Vries R, Perton FG, Dallinga-Thie GM et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in Type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 54(12), 3554-3559 (2005).
26. Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 95(1), 69-75 (1997).
27. Hoogeveen RC, Gaubatz JW, Sun W et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 34(5), 1069-1077 (2014).
28. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124(19), 2065-2072 (2011).
29. Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J. Am. Heart Assoc. 1(2), jah3-e000232 (2012).
30. Atzmon G, Rincon M, Schechter CB et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol. 4(4), e113 (2006).
31. Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362(12), 1082-1089 (2010).
32. Holmberg R, Refai E, Hoog A et al. Lowering apolipoprotein CIII delays onset of Type 1 diabetes. Proc. Natl. Acad. Sci. USA 108(26), 10685-10689 (2011).
33. Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J. Clin. Lipidol. 6(5), 413-426 (2012).
34. Olivecrona G, Ehrenborg E, Semb H et al. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J. Lipid Res. 51(6), 1535-1545 (2010).
35. Gaudet D, Methot J, Dery S et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20(4), 361-369 (2013).
36. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome Arterioscler. Thromb. Vasc. Biol. 28(1), 39-46 (2008).
37. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102(1), 21-27 (2000).
38. Bloomfield Rubins H, Davenport J, Babikian V et al. Reduction in Stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Circulation 103(23), 2828-2833 (2001).
39. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 230(2), 381-389 (2013).
40. Itakura H, Yokoyama M, Matsuzaki M et al. Relationships between plasma fatty acid composition and coronary artery disease. J. Atheroscler. Thromb. 18(2), 99-107 (2011).
41. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Euro. Heart J. 31(2), 149-164 (2010).
42. Nessim SA, Chin HP, Alaupovic P, Blankenhorn DH. Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass. Effect on blood lipids and apolipoproteins. Arterioscler. Thromb. Vasc. Biol. 3(6), 568-573 (1983).
43. Ruparelia N, Digby JE, Choudhury RP. Effects of niacin on atherosclerosis and vascular function. Curr. Opin. Cardiol. 26(1), 66-70 (2011).
44. Nicholls SJ. Niacin's effect on cardiovascular risk: have we finally learned our lesson Cleve. Clin. J. Med. 81(5), 275-277 (2014).
45. Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World J. Nephrol. 1(6), 184-194 (2012).
46. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J. Am. Coll. Cardiol. 59(17), 1521-1528 (2012).
47. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104(25), 3046-3051 (2001).
48. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735-742 (2010).
49. Staels B, Vu-Dac N, Kosykh VA et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95(2), 705-712 (1995).
50. Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoproteinassociated phospholipase A2 mass in men and women with mixed dyslipidemia. J. Clin. Lipidol. 5(6), 483-492 (2011).
51. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489(1), 31-44 (1999).
52. Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 6(6), 969-980 (2013).
53. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33(12), 1451-1458 (2012).
54. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9), 1022-1032 (2014).
55. Graham MJ, Lee RG, Bell TA 3rd et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circulation Res. 112(11), 1479-1490 (2013).
56. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 54(3), 664-671 (2005).
57. Gaudet D, Brisson D, Tremblay K et al. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371(23), 2200-2206 (2014).
58. Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler. Thromb. Vasc. Biol. 31(3), 471-473 (2011).
59. Prakash TP, Graham MJ, Yu J et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic acids Res. 42(13), 8796-8807 (2014).